tiprankstipranks

Telix Pharmaceuticals Announces Director’s Interest Change

Story Highlights
Telix Pharmaceuticals Announces Director’s Interest Change

Telix Pharmaceuticals Ltd. ( (AU:TLX) ) has issued an announcement.

Telix Pharmaceuticals Ltd. has announced a change in the director’s interest notice, specifically involving Dr. Christian Behrenbruch. The change involves the disposal of 46,558 Performance Share Appreciation Rights, reducing the total held by Dr. Behrenbruch. This update reflects ongoing adjustments in the company’s executive shareholding structure, which may impact stakeholder perceptions and the company’s market positioning.

More about Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals Ltd. operates in the biopharmaceutical industry, focusing on the development of diagnostic and therapeutic products using molecularly targeted radiation. The company primarily targets oncology and rare diseases, aiming to provide innovative solutions for unmet medical needs.

YTD Price Performance: 14.50%

Average Trading Volume: 4,747

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $5.85B

For an in-depth examination of TLX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App